Quanta Inc (fka QNTA)

[budfoxfun]

Big news this week! BURBANK, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company submitted the final clinical trial data to the Dominican Republic (“DR”) Ministry of Health (“MoH”) for approval of the Company’s product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus.

After the recent meeting between Medolife CEO Dr. Mikaelian and DR Vice-President Raquel Peña de Antuña that concluded with interest from the government to register the product as a treatment for COVID-19 in the country, the Company was required to present data to various governmental institutions prior to receiving a governmental order for Escozine, such as:

Program for Essential Medicines and Logistical Support Center (“PROMESE/CAL”)

National Health Insurance (“SeNaSa”)

High-Cost Medicines and Medical Assistance Program (“PMAC”)